APLIKASI ANALISIS KIMIA KUANTITATIF UNTUK PEMANTAUAN KADAR OBAT (THEURAPETIC DRUGS MONITORING)
DOI:
https://doi.org/10.22373/amina.v1i1.8Keywords:
Theurapetic drugs monitoring, immunoassays, chromatographyAbstract
Theurapetic drugs monitoring (TDM) is used to adjust individual drug therapy. TDM purpose is to maximize the therapeutic effect and reduce the side or toxic effects of the drug. In general, TDM includes sample preparation, conducting drug analysis and interpreting the concentration of the drug. The development of analytical techniques resulted in the determination of pharmacokinetic characters by measuring drug concentrations in the blood more easily. Drug analysis can be done by spectrophotometric, chromatographic or immunoassay methods. Immunoassay could provide fast results and easy to use, but this method cannot distinguish between drugs that have similar structures. In addition, immunoassays are not available for all drugs monitored in clinical laboratories, so chromatographic methods such as GC, HPLC, GC/MS, and HPLC / MS can still be applied to TDM.
References
Dasgupta, A., Datta, P. (2008). Analytical Techniques for Measuring Concentrations of Therapeutic Drugs in Biological Fluids, in: Dasgupta, A. (Ed.), Handbook of Drug Monitoring Methods. Humana Press, Totowa, NJ, pp. 67–86. https://doi.org/10.1007/978-1-59745-031-7_3
Gawade, S.P. (2016). Overview on Monitoring of Therapeutic Drugs. Indian J. Pharm. Pract. 9, 152–156. https://doi.org/10.5530/ijopp.9.3.4
Ghiculesco, R. (2008). Abnormal laboratory results: Therapeutic drug monitoring: which drugs, why, when and how to do it. Aust. Prescr. 31, 42–44. https://doi.org/10.18773/austprescr.2008.025
Gross, A.S. (1998). Best practice in therapeutic drug monitoring 5.
Hazarika, I. (2015). Therapeutic Drug Monitoring (TDM): An Aspect of Clinical Pharmacology and Pharmacy Practice. Ther. Drug Monit. 9.
Kang, J.-S., Lee, M.-H. (2009). Overview of Therapeutic Drug Monitoring. Korean J. Intern. Med. 24, 1. https://doi.org/10.3904/kjim.2009.24.1.1
Marshall, W., Bangert, S. (2008). Clinical Chemistry, 6th Edition. Mosby Elsevier, Edinburgh, London.
Reynolds, D.J., Aronson, J.K. (1993). ABC of monitoring drug therapy. Making the most of plasma drug concentration measurements. BMJ 306, 48–51. https://doi.org/10.1136/bmj.306.6869.48
Smith, T., Butlaer, V., Haber, E. (1969). Determination of Therapeutic and Toxic Serum Digoxin Concentration by Radio Immunoassay. N Eng J Med. 281, 1212–1216p.
Suthakaran, C., Adithan, C. (2006). Therapeutic Drug Monitoring – Concepts, Methodology, Clinical Applications And Limitations. Health Administrator XIX, 22–26.
Sym, D., Smith, C., Meenan, G., Lehrer, M. (2001). Fluorescence Polarization Immunoassay: Can It Result in an Overestimation of Vancomycin in Patients Not Suffering From Renal Failure?: Ther. Drug Monit. 23, 441–444. https://doi.org/10.1097/00007691-200108000-00020
Touw, D.J., Neef, C., Thomson, A.H., Vinks, A.A. (2005). Cost-Effectiveness of Therapeutic Drug Monitoring. Ther Drug Monit 27, 8.
Wright, J.D., Boudinot, F.D., Ujhelyi, M.R. (1996). Measurement and Analysis of Unbound Drug Concentrations: Clin. Pharmacokinet. 30, 445–462. https://doi.org/10.2165/00003088-199630060-00003
